Objective To explore the clinical effect of ivabradine treatment in patients with chronic systolic heart failure and its influence on echocardiographic indexes and plasma N-terminal natriuretic peptide precursor.Methods 109 patients with chronic systolic heart failure were randomly divided into two groups. The control group was given conventional drug treatment

and the observation group was treated with ivabradine on the basis of the control group. The clinical efficacy of the two groups was compared with echocardiographic indicators. N Terminal natriuretic peptide precursor（NT-proBNP）

serum calcitonin（PCT）

C-reactive protein（CRP） levels

and drug safety.Results After treatment

the clinical curative effect.LVEF level of the observation group was significantly higher than that of the control group. The IVS

LVPWT

LVEDD

LAD

CRP and PCT. NT-proBNP levels of the observation group were lower than those of the control group（p<0.05）

The incidence of adverse reactions was not statistically significant compared with the control group（p>0.05）. Conclusions Ivabradine treatment has a significant therapeutic effect on patients with chronic systolic heart failure. It can effectively maintain the patient’s ventricular structure

while significantly reducing the patient’s serum biochemical indicators

and has a high drug safety.